Logo

Companion Diagnostics

News on companion diagnostics and drug/test co-development.

Servier, Qiagen to Develop PCR-Based Companion Diagnostic to Identify IDH1-Mutant Leukemia

Qiagen will develop a real-time PCR-based in vitro diagnostic to identify patients eligible for Servier's Tibsovo and investigational IDH1-targeted agents.

Illumina, Myriad Genetics Expand Partnership to Bring TSO 500 HRD Assay to US

The firms are creating a CDx alliance to help pursue HRD regulatory approvals for both the MyChoice HRD assay and a future clinical IVD test from Illumina.

Point32Health Expands Coverage of Foundation Medicine CDx Tests for Patients With Advanced Cancer

FoundationOne CDx and FoundationOne Liquid CDx comprehensive genomic profiling tests will be available to Point32Health patients with advanced solid tumors.

Roche, Janssen Expand Companion Diagnostic Collaboration

The new agreement allows the companies to collaborate with multiple technologies, including digital pathology and immunoassays.

UnitedHealthcare to Cover Guardant360 for Approved CDx Indications in Lung, Breast Cancer

The move adds coverage for patients not eligible for coverage under Medicare, which currently pays for the test across all tumor types.

Feb 7, 2023

Genomenon, Flagship Biosciences Partner on Biomarker Discovery, Companion Dx Development

Jan 30, 2023

Guardant Health Nabs FDA Approval for Liquid Biopsy CDx With Menarini Breast Cancer Drug

Jan 24, 2023

Thermo Fisher Scientific, AstraZeneca to Develop Solid Tissue and Blood-Based CDx Test

Jan 23, 2023

Quest Diagnostics to Offer Agilent Companion Test for Mirati Therapeutics NSCLC Treatment

Jan 19, 2023

Foundation Medicine, Boehringer Ingelheim Collaborate on CDx for Biliary Tract Cancer Drug

Jan 11, 2023

Evolving Akoya Biosciences Touts CDx Partnerships at JP Morgan Conference

Jan 10, 2023

Foundation Medicine, Karyopharm Therapeutics Partnering on Endometrial Cancer CDx

Jan 6, 2023

Agilent, Akoya to Commercialize Workflow Tools for Tissue Biomarker Analysis

Jan 6, 2023

Qiagen, Helix Partner for Hereditary Disease CDx Development

Jan 4, 2023

FDA Approves Foundation Medicine Blood Test as CDx for Rozlytrek

Jan 4, 2023

Absent Resolution on FDA's LDT Oversight in 2022, Some Payors Began Advancing Their Own Requirements
Premium

Jan 4, 2023

Gene Expression Score IDs Breast Cancer Patients Responsive to Histone Deacetylase 6 Inhibitor
Premium

Dec 28, 2022

Mission Bio, Abiosciences to Develop Analytics For Studying Hematologic Cancers

Dec 21, 2022

FDA Approves Foundation Medicine Assay as CDx for Certain NSCLC Therapies

Dec 13, 2022

Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx

Dec 9, 2022

Guardant Health, AstraZeneca Partner on Liquid Biopsy CDx for Breast Cancer Drug

Dec 7, 2022

FDA Approves Thermo Fisher HLA Typing Test as CDx for Immunocore Uveal Melanoma Therapy

Nov 18, 2022

NeoGenomics, ImmunoGen Ink Testing Deal for Newly Approved Folate Receptor Drug

Oct 24, 2022

Molecular Tumor Board Therapy Matching Predicts Immunotherapy Best Responders
Premium

Oct 20, 2022

Drug, Diagnostic Developer HMNC Brain Health Raises €14.3M

Breaking News
The Scan

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.

Study Presents New Insights Into How Cancer Cells Overcome Telomere Shortening

Researchers report in Nucleic Acids Research that ATRX-deficient cancer cells have increased activity of the alternative lengthening of telomeres pathway.

Researchers Link Telomere Length With Alzheimer's Disease

Within UK Biobank participants, longer leukocyte telomere length is associated with a reduced risk of dementia, according to a new study in PLOS One.

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.